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A neurysmal subarachnoid hemorrhage (aSAH) is a devastating type of stroke with high morbidity 
and mortality.  The mortality is approx.  60%,  with 30% 
of survivors having significant morbidity.  Cerebral 
vasospasm (CVS) and microvascular dysfunction asso-
ciated with aSAH can decrease the cerebral blood flow,  
leading to delayed cerebral ischemia (DCI) and hypoxia 
in brain tissues and ultimately to severe neurological 
dysfunction [1].  These are major contributors to the 
high morbidity and mortality of aSAH patients.  A CVS 
usually occurs at around 4 days after the onset of aSAH 
and reaches a peak in incidence and severity at 7-10 
days [2].
There is substantial evidence to suggest that oxida-
tive stress,  inflammation,  alterations in the coagulation 
system,  and subsequent vascular endothelial injury are 
significant in the development of acute brain injury and 
CVS following aSAH.  The pathogenesis of CVS has not 
been fully clarified.  Various cytokine and protein pro-
files in serum or CSF have been investigated to elucidate 
this pathogenesis.  Although some biomarkers have 
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Cerebral vasospasm (CVS) is a major contributor to the high morbidity and mortality of aneurysmal subarach-
noid hemorrhage (aSAH) patients.  We measured histidine-rich glycoprotein (HRG),  a new biomarker of 
aSAH,  in cerebrospinal fluid (CSF) to investigate whether HRG might be an early predictor of CVS.  A total of 
seven controls and 14 aSAH patients (8 males,  6 females aged 53.4 ± 15.4 years) were enrolled,  and serial CSF 
and serum samples were taken.  We allocated these samples to three phases (T1-T3) and measured HRG,  inter-
leukin (IL)-6,  fibrinopeptide A (FpA),  and 8-hydroxy-2’-deoxyguanosine (8OHdG) in the CSF,  and the HRG in 
serum.  We also examined the release of HRG in rat blood incubated in artificial CSF.  In contrast to the other 
biomarkers examined,  the change in the CSF HRG concentration was significantly different between the non-
spasm and spasm groups (p< 0.01).  The rat blood/CSF model revealed a time course similar to that of the 
human CSF samples in the non-spasm group.  HRG thus appears to have the potential to become an early pre-
dictor of CVS.  In addition,  the interaction of HRG with IL-6,  FpA,  and 8OHdG may form the pathology of 
CVS.
Key words:  biomarker,  histidine-rich glycoprotein,  predictor,  subarachnoid hemorrhage,  vasospasm
Received July 27, 2018 ; accepted October 29, 2018.
＊Corresponding author. Phone : +81-87-870-1212; Fax : +81-87-870-1202
E-mail : tanakamu@kms.ac.jp (T. Nakamura)
Conflict of Interest Disclosures: No potential conflict of interest relevant 
to this article was reported.
shown a relationship with CVS,  an effective early pre-
dictor has not been found.  In addition,  the interactions 
between biomarkers are still unknown.
Histidine-rich glycoprotein (HRG) is a plasma gly-
coprotein produced in and secreted from the liver.  
Since HRG binds to a diverse range of ligands,  it has 
been suggested to be involved in the regulation of coag-
ulation/fibrinolysis [3-5],  immune response [6],  and 
angiogenesis [7-10].  HRG was also recently shown to 
have important effects on intravascular elements.  HRG 
inhibits the tight attachment of neutrophils,  sustains 
rheological stability,  and inhibits vascular endothelial 
cell activation [11 , 12].  This suggests that a loss of HRG 
might be involved in the endothelial injury that leads to 
a CVS.  However,  HRG in cerebrospinal fluid (CSF) has 
not been investigated.
The primary aims of the present retrospective study 
were to determine whether there is a difference in HRG 
concentration between patients who incurred an aSAH 
and those who did not,  and between patients who 
developed a vasospasm and those who did not.  We also 
investigated the usefulness of HRG as an early predictor 
of CVS.  A second goal was to determine whether HRG 
interacts with other potential biomarkers.  We measured 
and evaluated interleukin (IL)-6,  an inflammatory 
marker,  fibrinopeptide A (FpA),  a coagulation marker,  
and 8-hydroxy-2’-deoxyguanosine (8OHdG),  an oxi-
dative stress marker.
Materials and Methods
Ethical approval. For this type of retrospective 
study,  formal consent of the patients was not required.  
All applicable international,  national,  and/or institu-
tional guidelines for the care and use of animals were 
followed,  and all of the procedures in the present ani-
mal experiments were in accordance with the ethical 
standards of our institution.
Background characteristics. We retrospectively 
analyzed the cases of patients with aSAH and controls.  
They were of comparable age and gender.  We classified 
the aSAH patients into spasm and non-spasm groups.  
The aSAH patients were evaluated both at their admis-
sion with the Hunt and Kosnik grading (H & K grading) 
and the World Federation of Neurological Surgeons 
SAH scale (WFNS scale),  as well as at discharge using 
the modified Rankin Scale (mRS).
Aneurysmal neck clipping or coil embolization to 
prevent re-rupture was performed in the patients who 
were of treatment adaptation.  In addition,  in the spasm 
group,  we evaluated whether the patients developed a 
symptomatic spasm and/or DCI.  All assigned patients 
received medical treatment in our hospital’s intensive 
care unit for ≥ 2 weeks.  Standard prophylactic treat-
ments were performed to prevent vasospasm or DCI.  
Each CVS was detected by digital subtraction angiogra-
phy (DSA) or magnetic resonance angiography (MRA) 
7-9 days after its onset.  DCI was confirmed by com-
puter tomography (CT) or magnetic resonance imaging 
(MRI) with proper timing.  When it was thought neces-
sary for CSF drainage,  a spinal tube was inserted 
appropriately.  Each patient’s sample study was gathered 
at the same time that the CSF was submitted for a clini-
cal examination.
We enrolled the total of 40 aSAH patients who were 
admitted to Kagawa University Hospital from 
September 2014 to September 2016.  CSF and serum 
samples were gathered several times per patient 
between day 0 and day 11.  We allocated these samples 
to three phases (T1-T3).  We defined T1 as the period 
within 48 h following the patient’s SAH.  The T2 phase 
was after T1 and before the examinations for spasm.  T3 
was the phase after the spasm check.  Thus,  T1 reflects 
the period immediately after spasm onset,  T2 the early 
or pre-spasm phase,  and T3 the severe spasm phase.
We selected the cases of the patients in whom CSF 
samples could be gathered during T1 and T2 with or 
without T3,  and we investigated several biomarkers 
including HRG.  Serum HRG concentrations were cal-
culated in some of the enrolled patients who had stored 
samples.  We excluded the cases in which CSF samples 
were not obtained in the appropriate phase,  the cases in 
which the treatment for preventing re-rupture was not 
performed,  and the cases of patients who died during 
their follow-up or suffered severe meningitis.  The sam-
ple collection and retrospective analysis were approved 
by the Ethics Committee of Kagawa University.  We also 
investigated relationship the between the value of T1 
and the hematoma volume.  The semiquantitative clas-
sification of hematoma is as follows.  Each of 10 basal 
cisterns and fissures were graded separately on a semi-
quantitative scale according to the amount of extrava-
sated blood,  from 0 to 3.  The total amount of sub-
arachnoid blood (sum score) was calculated by adding 
the 10 scores,  and the possible sum thus ranged from 0 
to 30.  There was a dose-dependent relationship 
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between the T1 value and semiquantitative classifica-
tion of the hematomas.
CVS detection. At our facility,  all aSAH patients 
undergo preoperative DSA.  Thus,  when follow-up DSA 
is performed to check for a spasm,  the images obtained 
before and after treatment can be compared.  We classi-
fied the patients into a non-spasm group and a spasm 
group based on their DSA findings.  We further divided 
the spasm group into the subgroup of patients who had 
experienced an angiographic spasm (i.e.,  a CVS around 
the circle of Willis or a peripheral artery,  without neu-
rological defect,  including patients who had slight ste-
nosis compared with preoperative findings) and the 
subgroup of patients who had experienced a symptom-
atic spasm (i.e.,  a CVS with a neurological defect such 
as consciousness disorder,  paralysis,  and dysarthria).
Handling of CSF and serum samples. Within 
15 min of collection,  the CSF samples were centrifuged 
at 1,000 g for 15 min,  and the supernatants were col-
lected and stored at −80°C.  Before each assay was per-
formed,  high-molecular-weight proteins were removed 
by filtration (COSMOSIL,  Kyoto,  Japan).  Serum sam-
ples were first left to stand for 30 min and then centri-
fuged at 300 g for 10 min.  We did not use a reservoir for 
serum samples.  The samples were stored as for CSF.
Concentrations of HRG, IL-6, FpA, and 8OHdG.
We measured the targeted proteins and cytokines in the 
patients’ CSF and serum with commercial quantitative 
sandwich enzyme-linked immunosorbent (ELISA) 
assay kits.  HRG was measured by a kit from 
CUSABIO/CusAb (College Park,  MD,  USA),  IL-6 was 
measured by a kit from (R & D Systems,  Minneapolis,  
MN,  USA),  FpA measured by a kit from CUSABIO/
CusAb,  and 8OHdG measured by a kit from JaICA 
(Shizuoka,  Japan).
Standards were prepared and the appropriate volume 
of samples or standards were added to 96-well polysty-
rene microtiter plates pre-coated with a monoclonal 
antibody to HRG,  IL-6,  FpA,  or 8OHdG.  The plates 
were incubated for the time recommended by the 
ELISA kit’s manufacturer.  Each well was then aspirated,  
and the plates were washed with the buffered surfactant 
provided.  An enzyme-linked polyclonal antibody 
against each element was then added,  and the plates 
were incubated and washed.  Substrate solution was 
added to each well,  and the optical density was read at 
a wavelength of 450 nm.
Rat preparation and the incubation of blood/CSF.
To investigate the time course of the HRG concentra-
tion in CSF,  we made a rat blood/CSF model.  Three 
8-week-old Sprague-Dawley rats weighing approx.  
250 g had a femoral artery exposed and a catheter 
inserted in the aorta to obtain 0.5 ml of arterial blood.  
These aliquots were mixed with 9.5 ml of artificial CSF 
(Funakoshi,  Tokyo) and placed in an incubator at 37°C 
and aged under sterile conditions in the dark for 
≤ 240 h.  At 3 , 48 , 96 , 144 , 192 and 240 h,  1.0 ml of 
blood/CSF was harvested.  Each sample was centrifuged 
at 1,000 g for 15 min,  and the supernatant collected and 
stored at −80°C.  The HRG concentration was then 
measured with an ELISA kit from CUSABIO/CusAb.
ROC analysis. We obtained non-parametric 
receiver operating characteristic (ROC) curves and the 
area under the curve (AUC) to quantify how well HRG 
discriminated between the spasm and non-spasm 
groups.  The AUC can be considered a simple measure 
of the probability that a randomly selected case would 
have a higher biomarker value than a control.
Statistical analysis. Data are presented as the 
mean ± standard deviation (SD).  The statistical analy-
ses were done with StatMate V software (ATMS,  Tokyo,  
Japan).  We used Welch’s t-test or an analysis of variance 
(ANOVA) which is supported by LSD (least significant 
difference) to analyze the data.  Statistical significance 
was defined as p < 0.05.
To clarify the precise utility of HRG,  we calculated 
the sensitivity,  specificity,  and AUC by obtaining the 
(ROC) curves with the use of JMP 13 software (SAS,  
Cary,  NC,  USA).
Results
Table 1 summarizes the background characteristics 
of the patients.  Of the 40 patients who suffered an 
aSAH during the target period,  26 were excluded.  A 
spinal tube was not inserted in 15 patients.  CSF was not 
collected in 10 patients with the proper timing.  One 
patient suffered from bacterial meningitis because of the 
spinal tube during observation.  No patient was pre-
vented from undergoing treatment for re-rupture pre-
vention,  and no patient died during their observation 
period.
The 14 enrolled patients were 8 males and 6 females 
aged 53.4 ± 15.4 years (range 32-84 years).  Of the aSAH 
group,  7 patients incurred a CVS.  Of these,  3 patients’ 
condition developed to an angiographical CVS and 4 to 
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a symptomatic CVS.  Of the symptomatic CVS group,  1 
patient received an intra-arterial injection of fasudil 
hydrochloride hydrate,  and 3 underwent a balloon 
angioplasty.  However,  notwithstanding this aggressive 
treatment,  1 patient developed DCI.
The non-spasm patients and the spasm patient did 
not differ significantly by age,  gender,  SAH grade 
(H & K grading,  WFNS grading),  surgical procedure 
(coil/clip rate) or mRS at discharge.  The sampling 
interval for CSF allocated to the T1,  T2 and T3 phases 
also did not differ between these 2 patient groups.  
Among the patients who suffered an aSAH,  10 (4 
spasm patients,  6 non-spasm patients) had their serum 
HRG concentrations measured in addition to their CSF 
HRG levels.
Seven patients (5 males,  2 females) were enrolled as 
the control group.  Five had idiopathic normal pressure 
hydrocephalus (iNPH) and two had a benign brain 
tumor.  The controls were older than the aSAH patients 
at 66.9 ± 20.6 years.
Fig. 1 compares the CSF HRG concentrations in the 
aSAH groups and controls in the initial T1 time period.  
Significantly higher HRG levels were revealed in the 
aSAH group (324.9 ± 300.5 μg/ml) compared to the con-
trol group (54.3 ± 19.3 μg/ml; p < 0.05),  and the spasm 
group’s HRG levels were higher than those of the non-
spasm group (133.4 ± 68.5 μg/ml),  but not significantly 
so.
We also investigated whether there is a relationship 
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Table 1　 Patient demographics
Control group aSAH group p value
N 7 14
spasm nonspasm
7 7
Age 66.9±20.6 57.3±16.2 56.4±15.0 NS
Gender (male: female) 5 : 2 4 : 3 4 : 3 NS
SAH grading
H&K grade NS
I 0 0
II 4 3
III 1 1
IV 1 2
V 1 1
WFNS gradc NS
I 2 1
II 3 2
III 0 0
lV 0 2
V 2 2
Tl (day) 0.57±0.53 0.50±0.55 NS
T2 (days) 4.71±1.38 5.17±1.47 NS
T3 (days) 8.71±1.98 8.67±1.21 NS
Surgical procedure (coil: clipping) 5 : 2 6 : 1 NS
Symptomatic spasm 4
DCI 1
mRS 2.57±1.6 2.00±1.5 NS
＊p<0.05
Fig. 1　 The CSF HRG concentrations during the T1 period in the 
control,  non-spasm,  and spasm aSAH patients.  The HRG levels 
were signiﬁcantly higher in the spasm aSAH patients compared to 
the controls and higher in the spasm group than the non-spasm 
group.
between the T1 value and hematoma volume.  Each of 
10 basal cisterns and fissures were graded separately on 
a semiquantitative scale,  according to the amount of 
extravasated blood from 0 to 3.  The total amount of 
subarachnoid blood (sum score) was calculated by add-
ing the 10 scores,  providing a possible total score from 
0 to 30 [13].  The results indicated a positive correlation 
between the T1 value and hematoma volume (Fig. 2).
Fig. 3A, B shows the time courses of the patients’ 
CSF and serum HRG concentrations during phases 
T1-T3 in the aSAH group.  The standard value of serum 
concentration was set based on a previous report [6],  
and we calculated the standard value of the CSF con-
centration based on the average value of control group.  
In both the aSAH and control groups,  the serum HRG 
concentrations were almost the same as the standard,  
and the amount of change with time was small.  In con-
trast,  the CSF HRG concentrations were extremely high 
in both aSAH groups compared to the average of the 
control group.
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A B
C ＊p<0.01
Fig. 3　 The CSF HRG concentrations in the T1-T3 phases in the non-spasm (A) and spasm (B) aSAH groups.  Black dotted line: The 
average CSF concentration in the control patients.  Gray dotted line: The mean serum HRG concentration.  In both the non-spasm and 
spasm groups,  the serum HRG concentrations were almost the same as those of the control patients,  and the amount of change with time 
was small.  In contrast,  the CSF HRG concentrations were much higher in both aSAH groups compared to the controls,  and this diﬀerence 
persisted with time.  C,  The changes in the CSF HRG concentration at T2 and T3 compared to T1 (set as 0).  In the non-spasm aSAH 
group,  the T2 and T3 values were higher than the T1 values,  whereas they were signiﬁcantly lower in the spasm group (p＜0.01).
1,000
Fig. 2　 The relationship between the T1 value and the hematoma volume.  The results indicate a positive correlation (p＜0.01).
We use the CSF data to calculate the change in the 
HRG level with time,  with T1 set as zero (Fig. 3C).  In 
the non-spasm group,  the T2 and T3 values were 
higher than the T1 values (changes from T1 at T2:  
37.7 ± 86.1 μg/ml,  at T3: 87.3 ± 184.2 μg/ml).  In con-
trast,  the T2 and T3 values were lower in the spasm 
group compared to the T1 values (changes from T1 at 
T2: −107.2 ± 113.2 μg/ml,  T3: −69.6 ± 136.2 μg/ml).  
There were significant differences among the groups 
(p < 0.01).  However,  there was no difference between 
the angiographic spasm and symptomatic spasm groups 
(data not shown).  The detailed data for each patient are 
shown in Fig. 4.
Fig. 5 shows the time courses of the IL-6,  FPA,  and 
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Fig. 4　 Each patientʼs HRG concentration changes.  The HRG concentration tended to rise in the non-spasm group and tended to 
decline in the spasm group.
NS(p=0.40)
NS(p=0.26) NS(p=0.055)
NS(p=0.053)
NS(p=0.14)
NS(p=0.48)
NS(p=0.32)
5,000
4,000
3,000
2,000
1,000
0
A B
C
Fig. 5　 The time courses of potential biomarkers in the CSF in the spasm and non-spasm aSAH patients.  A,  The IL-6 concentrations 
during phases T2 and T3 were higher than those in T1 in both groups.  In the spasm group,  the concentration reached a maximum in T3.  In 
the non-spasm group,  after the concentration reached a maximum during T2,  the concentration decreased.  There were no signiﬁcant dif-
ferences between the spasm and no-spasm groups at any time point,  although at T3 the spasm group was nearly signiﬁcantly higher (p＝
0.055); B,  The CSF FpA concentration in both groups was highest in T1,  and rapidly decreased.  All T2 and T3 samples in both groups 
were below the measurement sensitivity (p＜0.039 ng/ml).  In T1,  the CSF FpA concentration was higher in the spasm group,  but this was 
not quite signiﬁcant (p＝0.053) ＊Below the measurement sensitivity; C,  In both the spasm and non-spasm groups,  the CSF 8OHdG con-
centrations were highest in T1 and gradually decreased.  There were no signiﬁcant diﬀerences between the two groups at any time point.
8OHdG concentrations in CSF.  As with HRG,  these 
concentrations were measured at the T1,  T2 and T3 
time periods.  Regarding IL-6,  in both groups,  the CSF 
concentrations at T2 and T3 were higher than at T1 
(spasm group,  T1: 2,840±1,884 pg/ml,  T2: 3,028±  
1,825 pg/ml,  T3: 4,089 ± 1,274 pg/ml; non-spasm 
group,  T1: 2,593 ± 1,766 pg/ml,  T2: 3,662 ± 1,768 pg/
ml,  T3: 2,666 ± 1,626 pg/ml).  The Il-6 concentration 
gradually increased and reached a maximum at T3 in 
the spasm group.
In contrast,  in the non-spasm group,  the Il-6 con-
centration decreased after it reached a maximum at T2.  
During T3,  the IL-6 concentration was higher in the 
spasm group than the non-spasm group,  but this did 
not quite reach significance (p = 0.055,  Fig. 5A).  The 
concentrations of FpA were highest at T1 (spasm group:  
1.47±1.33 ng/ml,  non-spasm group: 0.29± 0.57 ng/ml) 
and then rapidly decreased.  All of the T2 and T3 sam-
ples in both groups were below measurement sensitivity 
(< 0.039 ng/ml).  The T1 concentration of FpA was 
higher in the spasm group,  but this did not quite reach 
significance (p = 0.053,  Fig. 5B).  As for 8OHdG,  the T1 
concentrations were the highest (spasm group:  
10.3 ± 10.2 μg/ml,  non-spasm group: 7.0 ± 2.1 μg/ml),  
and the concentrations then gradually decreased (spasm 
group,  T2: 3.9 ± 0.1 ng/ml,  T3: 3.8 ± 0.7 ng/ml; non-
spasm group,  T2: 4.0± 2.2 ng/ml,  T3: 3.2± 0.5 ng/ml).  
However,  there were no significant differences between 
the spasm and non-spasm groups (Fig. 5C).
Fig. 6 shows the time course of the HRG concentra-
tions in the rat blood/CSF incubation model.  The con-
centration was measured at 3 , 48 , 96 , 144 , 192,  and 
240 h after blood/CSF incubation.  The HRG concentra-
tion peaked at 48 h and decreased thereafter.  However,  
all of the values after 48 h were higher than the 3 h value.  
This HRG time course was similar to that found for CSF 
in the samples from the non-spasm patients.
Fig. 7 shows the ROC curves regarding the predic-
tion of CVS at arbitrarily chosen HRG cutoff values.  We 
used the amount of change in the T2 values with T1 set 
as zero.  The cutoff value of −36.6 μg/ml for HRG 
showed 85.7% sensitivity and 71.4% specificity for the 
prediction of a CVS during the T2 phase.  The AUC of 
this ROC was 85.7%.
Discussion
We consider the following hypothesis regarding the 
etiology of CVS.  As the first step,  a strong coagulation 
disorder occurs,  which leads to a decrease in HRG that 
is caused by the consumption.  The decrease in HRG 
also induces inflammation.  A series of cascades causes 
a vascular endothelial injury,  resulting in a CVS.
HRG is a 75-kDa plasma glycoprotein produced in 
and secreted from the liver [14].  It is thought to be 
involved mainly in the regulation of coagulation and 
fibrinolysis.  HRG inhibits the contact pathway activa-
tion of plasma in vitro,  presumably because the histi-
dine-rich region of HRG binds to negatively charged 
surfaces and prevents the auto-activation of FXII (coag-
ulation factor XII) [3 , 4].  In support of this concept,  
HRG-deficient mice exhibit shortened clotting times [5].  
On the other hand,  it was also reported that HRG par-
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(h)
Fig. 6　 The HRG concentration time course after blood/CSF 
incubation.  The concentration peaked at 48h and decreased there-
after.  However,  all of the samples after the 48-h value were still 
higher than the 3-h value.
Fig. 7　 ROC curves regarding the prediction of CVS.
ticipates in the immune response [6] and angiogenesis 
[7-10].  Interestingly,  Wake et al.  have clearly shown a 
novel and important role of HRG in controlling neutro-
phil shape,  adhesiveness,  and basal reactive oxygen 
species (ROS) producing activity [8].  The neutrophil 
shape maintained by HRG should be suitable for the 
passage of neutrophils through capillary vessels,  sus-
taining rheological stability,  and preventing the unnec-
essary activation of endothelial cells that can lead to 
vascular injury.  Thus,  decreased HRG may lead to 
vascular injury and the production of inflammatory 
cytokines such asIL-6.
Plasma HRG concentrations in healthy humans are 
reported to be constant at approx.  1 mM [6].  However,  
the CSF concentrations of HRG have never been 
reported.  In the present study,  we considered the aver-
age value of the control group as a standard value,  
approx.  0.7 μM.  The HRG concentrations in the CSF of 
our aSAH patients were extremely high for the entire 
study period compared to the standard value.  In con-
trast,  the drastic changes observed in the CSF were not 
seen in the patients’ serum.  It is likely that we were not 
able to detect changes in the serum because pathologi-
cal changes in aSAH occur locally in the subarachnoid 
space.  Thus,  for further examinations of the impor-
tance of HRG,  CSF concentrations are more useful than 
those in serum.
The relationship between biomarkers and CVS.
Understanding the pathophysiology of CVS and early 
risk assessment are still major challenges in SAH.  A 
CVS occurs due to the continuous contraction of one or 
several areas of smooth muscle in the intracranial vas-
culature,  or vascular injury,  which leads to changes in 
the luminal morphology and intracranial vascular ste-
nosis or spasm [15].  Various biomarkers (e.g.,  inflam-
matory,  oxidative stress,  and coagulation system mark-
ers) have been investigated in SAH,  and we examined 
such biomarkers to judge their usefulness compared 
with HRG.  We selected IL-6 as an inflammatory 
marker,  FpA as a coagulation system marker,  and 
8OHdG as an oxidative stress marker.
IL-6 is a pleiotropic inflammatory cytokine of low 
molecular weight [16].  After an aSAH,  the CSF con-
centration of IL-6 peaks at 6-7 days and declines by 
approx.  10 days [17].  These findings suggested that a 
severe inflammatory response occurs in the brain.  
Unfortunately,  inflammation in CSF can induce a per-
sistent and severe CVS [18].  Emerging evidence indi-
cates that high concentrations of IL-6 in the plasma or 
in the CSF are associated with a significant high risk of 
CVS,  DCI,  and poor outcome after aSAH [19-24].  It 
was also indicated that IL-6 not only reflects a current 
vasospasm but may also be an early biomarker for pre-
dicting vasospasm after SAH [25 , 26].  Our present 
results support this idea.  In our spasm group,  the max-
imum IL-6 concentrations were confirmed at the T3 
phase,  suggesting persistent inflammation in CVS cases.
Fibrinopeptide A is cleaved from fibrinogen by 
thrombin during coagulation [27-29].  When an aSAH 
occurs,  the balance between the coagulation and fibri-
nolytic systems in the CSF is altered.  It is thus under-
standable that various coagulation factors were reported 
to be more strongly activated within 3 days after an 
aSAH [30].  Kasuya et al.  observed extremely high FpA 
levels in the CSF of patients during the immediate post-
aSAH phase compared to healthy humans [31].  Higher 
concentrations of FpA have been reported in DCI com-
pared to non-DCI patients [32-34].  These changes 
occurred within 48 h of aSAH onset.  Subsequently,  the 
FpA concentration rapidly decreased in both groups 
[34].  In the present study,  the FpA concentrations 
during the T1 period were higher in the spasm group,  
indicating that the coagulopathy in the CSF was more 
marked in this group.  As in previous reports,  the FpA 
concentration decreased rapidly.  Thus,  the changes in 
coagulopathy in the CSF during the immediate phase 
may be related to CVS indirectly or directly.
8-Hydroxy-2’-deoxyguanosine,  derived from a 
hydroxyl radical attack of deoxyguanosine residues,  is 
the most representative product of DNA oxidative 
modification [35 , 36].  Oxidative stress plays a signifi-
cant role in the processes of acute brain damage after 
SAH as well as cerebral vasospasm [37].  It was shown 
that 8OHdG peaks at day 2 after SAH and then gradu-
ally decreases and correlates to CVS and following DCI 
[38 , 39].  We observed no clear difference in the 
8OHdG concentration between our non-spasm and 
spasm groups.  However,  the finding that the peak CSF 
8OHdG concentration occurred during the immediate 
(T1) period suggests that oxidative stress occurs in the 
immediate phase after an aSAH.
The relationship between HRG and CVS. This is,  
to the best of our knowledge,  the first publication 
studying HRG concentrations in the CSF during the 
acute phase of aSAH.  Our extensive literature search 
revealed only one article reporting an influence of HRG 
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on cerebral arteries; those researchers reported that 
HRG causes a dose-dependent dilation of porcine cere-
bral arterioles [40].  A decrease in HRG may thus result 
in cerebral vessel contraction.  We observed that the 
CSF HRG concentration in the T1 period correlated 
with the hematoma volume.  Considering that the HRG 
concentrations in T1 were higher in the spasm group,  
we speculate that a hematoma in the subarachnoid 
space affects the development of a CVS,  as other 
researchers have suggested.  There were also more 
remarkable differences among the groups during the T2 
phase; the HRG concentration was decreased in the 
spasm group whereas it increased in the non-spasm 
group.  During T3,  a similar tendency was observed.
In the blood/CSF rat model,  the HRG concentra-
tion followed a time course that was similar to that of 
the CSF HRG concentration in the human non-spasm 
group.  The increased HRG concentration may be due to 
the release of free HRG found in plasma as well as the 
release of HRG stored in the α-granules of platelets 
[41 , 42].  We thus suggest that the consecutive release of 
HRG from an aging clot caused the local increases in 
HRG in the human non-spasm group and in the blood/
CSF model.  Samantha et al.  measured the time course 
of the HRG release from aging clots [40],  and they 
found that the HRG concentration was significantly 
elevated during 24-72 h of culture,  which is in agree-
ment with our results.  The decrease in CSF HRG with 
time in our group of spasm patients may be related to 
pathological changes triggered in that group.
Our evaluation of biomarkers in CSF related to CVS 
in aSAH patients demonstrated that increased FpA at 
T1,  decreasing levels of HRG at T2,  and increased IL-6 
levels at T3 occurred in the spasm group.  In addition,  
although no clear differences between the spasm and 
non-spasm groups were observed,  increased 8OHdG in 
the immediate phase was confirmed in the spasm group.
A proposed pathological mechanism underlying 
CVS based on these results is as follows.  In the CSF of 
aSAH patients who develop a CVS,  first,  a strong coag-
ulation disorder occurs,  and then HRG decreases due to 
metabolism/clearance and induces inflammatory cyto-
kines.  These cytokines cause vascular endothelial 
injury,  resulting in a CVS.  This proposed pathway sug-
gests that HRG may form a part of a pathologic pathway 
in CVS.  To test these hypotheses,  additional experi-
ments are necessary.
The usefulness of HRG as an early predictor of 
spasm. We examined the usefulness of the CSF level 
of HRG for predicting a spasm,  in a comparison with 
three other biomarkers.  Our results suggested but did 
not prove a relationship between the FpA and IL-6 con-
centrations with CVS.  On the other hand,  we did not 
detect a difference in the CSF 8OHdG levels between 
the spasm and non-spasm groups.  Various biomarkers 
— including those in the present study — have been 
examined,  but no useful early predictor for CVS has 
been established.  In our study,  the CSF’s level of HRG 
decreased at the T2 phase in the spasm group,  with a 
significant difference between the spasm and non-
spasm aSAH groups.  We examined whether HRG 
might become an early predictor of CVS.  The useful-
ness of HRG during the T2 period was statistically 
excellent.  The T2 period is before DSA or MRA is per-
formed to check for a spasm in angiographic spasm 
patients,  and before suffering from neurological deficits 
in the symptomatic spasm group.  HRG may thus 
become a biomarker that can detect changes in the early 
or preliminary phase of a CVS,  and its diagnostic use-
fulness may be extremely high.
Regarding possible limitations of the present study,  
the number of samples and the collection days were not 
uniform,  as the CSF samples of aSAH patients were 
examined retrospectively.  The pathophysiology of 
aSAH can vary by individual,  and the onset day of a 
neurological deficit with a symptomatic spasm can also 
differ.  Therefore,  we do not know whether we can allo-
cate such diversity into three time periods uniformly.  In 
addition,  in the patients with a mild SAH,  the hema-
toma was washed out around onset day 10 and their 
HRG markedly decreased,  causing unevenness in the 
data.  A prospective study is needed to resolve these 
issues.  In such a study,  we will increase the number of 
samples per patient and sample at fixed intervals.
In conclusion,  we investigated the time course of 
HRG in the cerebrospinal fluid after aSAH patients for 
the detection of a cerebral vasospasm.  The results sug-
gest that the CSF concentration of HRG has the possi-
bility to become an early predictor of CVS.  In addition,  
the interactions of HRG with IL-6,  FpA and 8OHdG 
may form part of the pathology of CVS.  A future pro-
spective study will investigate the relationship between 
the pathology of CVS and HRG.
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